
Ratings Moves: AIR,...


| Price and Volume | |
|---|---|
| Recent Price | 3.17 |
| 52 Week High | 7.47 |
| 52 Week Low | 2.94 |
| Avg. Daily Vol. (Mil) | 0.33 |
| Beta (3 year) | 0.80 |
| Share Related Items | |
| Mkt Cap (Mil) | 138.62 |
| Shares Out (Mil) | 43.73 |
| Float (Mil) | 24.55 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | n.a. |
| Financial Strength | |
| Quick Ratio | 1.60 |
| Current Ratio | 1.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 1.46 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.29 |
| Price/Book | 1.74 |
| Price/Cash Flow | 20.60 |
| Per Share Data | |
| Earnings | 0.00 |
| Sales | 0.96 |
| Book Value | 1.82 |
| Cash Flow | 0.15 |
| Business Summary | |
|---|---|
| Enzon Pharmaceuticals, Inc. is engaged in the research and development of therapeutics for cancer patients primarily in the United States. | |
| General Information | |
| 20 Kingsbridge Road
Piscataway, NJ 08854 |
|
| www.enzon.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 21 | |
| CEO: Mr. George W. Hebard, II | |
| Short Interest | |
| Current Month (Mil) | 2.14 |
| Previous Month (Mil) | 1.90 |
| Short Interest Ratio (Days) | 5.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -0.20 |
| Return on Investments | -0.50 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -12.50 |
| Profit Margin | -0.90 |